The comparative bioavailability of cimetidine-alginate treatments.
The comparative bioavailability of cimetidine in cimetidine-alginate combinations has been investigated in twelve healthy volunteers in an open crossover study. Each volunteer received a single oral dose of a commercially available alginate-cimetidine combination tablet (Algitec) or cimetidine tablets (Tagamet), co-administered with a commercially available alginate reflux suppressant liquid or tablet (Gaviscon). No significant differences were observed between treatments for Cmax, tmax, AUC0-12 or AUC0- infinity. The study demonstrated equivalent bioavailability of cimetidine when administered separately with alginate products and as a fixed dose combination product.
Britton
A M
AM
Reckitt and Colman Pharmaceuticals, Kingston-Upon-Hull, UK.
Nichols
J D
JD
Draper
P R
PR
D000284:Administration, Oral; D000328:Adult; D000464:Alginates / Q000494:pharmacology*; D001682:Biological Availability; D002927:Cimetidine / Q000097:blood / Q000493:pharmacokinetics*; D004338:Drug Combinations; D005260:Female; D020723:Glucuronic Acid; D006207:Half-Life; D006490:Hemostatics / Q000494:pharmacology*; D006603:Hexuronic Acids; D006801:Humans; D008297:Male
D000464:Alginates; D004338:Drug Combinations; D006490:Hemostatics; D006603:Hexuronic Acids; D002927:Cimetidine; D020723:Glucuronic Acid